Taxane-Mediated Antiangiogenesis in Vitro
- 1 February 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (3) , 821-824
- https://doi.org/10.1158/0008-5472.can-03-3391
Abstract
Paclitaxel (Taxol) and docetaxel (Taxotere) have been shown to inhibit angiogenesis at low concentrations that do not affect cancer cell proliferation. Here, we used rat aortic rings and human umbilical vein endothelial cells to evaluate the influence of their formulation vehicles Cremophor EL and polysorbate 80, as well as serum binding proteins on taxane-mediated antiangiogenesis. The data show that clinically relevant concentrations of the vehicles and binding proteins nullify the antiangiogenic activity of both taxanes. It is suggested that these agents may need to be used at much higher doses than anticipated for effective antiangiogenic chemotherapy.Keywords
This publication has 8 references indexed in Scilit:
- Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteinsPublished by Wiley ,2003
- Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)International Journal of Cancer, 2003
- Pharmacological Effects of Formulation VehiclesClinical Pharmacokinetics, 2003
- Docetaxel Versus Paclitaxel for AntiangiogenesisJournal of Hematotherapy & Stem Cell Research, 2002
- Redefining the Target: Chemotherapeutics as AntiangiogenicsJournal of Clinical Oncology, 2001
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- Potentiation of Anticancer-Drug Cytotoxicity by Multidrug-Resistance Chemosensitizers Involves Alterationsin Membrane Fluidity Leading to Increased Membrane PermeabilityEuropean Journal of Biochemistry, 1995
- Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantreneBiochemical and Biophysical Research Communications, 1986